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Background: Women require information about the impact of regularly attending screening mammography on breast cancer
mortality and overdiagnosis to make informed decisions. To provide this information we aimed to meta-analyse randomised
controlled trials adjusted for adherence to the trial protocol.
Methods: Nine screening mammography trials used in the Independent UK Breast Screening Report were selected. Extending an
existing approach to adjust intention-to-treat (ITT) estimates for less than 100% adherence rates, we conducted a random-effects
meta-analysis. This produced a combined deattenuated prevented fraction and a combined deattenuated percentage risk
of overdiagnosis.
Results: In women aged 39–75 years invited to screen, the prevented fraction of breast cancer mortality at 13-year follow-up was
0.22 (95% CI 0.15–0.28) and it increased to 0.30 (95% CI 0.18–0.42) with deattenuation. In women aged 40–69 years invited to
screen, the ITT percentage risk of overdiagnosis during the screening period was 19.0% (95% CI 15.2–22.7%), deattenuation
increased this to 29.7% (95% CI 17.8–41.5%).
Conclusions: Adjustment for nonadherence increased the size of the mortality benefit and risk of overdiagnosis by up to
50%. These estimates are more appropriate when developing quantitative information to support individual decisions about
attending screening mammography.
Screening mammography can help and harm. The Independent
UK Panel on Breast Cancer Screening stated that mammography
has the potential to reduce a woman’s risk of dying from breast
cancer, but that this must be balanced against the possibility of
physical, psychological and financial harm because of unnecessary
diagnosis and treatment (Marmot et al, 2013). There is interna-
tional recognition of the need to develop objective information on
the benefits, harms and uncertainties of screening mammography
to accompany invitations to screening (Canadian Task Force on
Preventive Health Care, 2011; Marmot et al, 2013; Biller-Andorno
and Ju¨ni, 2014; Depypere et al, 2014). To aid women with
informed decision making, material should present information
about, and numerical outcomes of, breast cancer mortality
reduction and overdiagnosis – also termed overdetection – of
screening mammography (Elwyn et al, 2006). Clear and balanced
information that is relevant and appropriate for individuals
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can help women assess the trade-offs using their own values and
preferences (Jørgensen et al, 2009; Pace and Keating, 2014; Hersch
et al, 2015).
Randomised controlled trials (RCTs) are the most rigorous
method of establishing numerical estimates and can determine
whether a causal relationship exists between an intervention and
outcome. Participants are generally analysed in the groups to
which they were allocated, regardless of missing outcome data or
nonadherence to the trial protocol (Hollis and Campbell, 1999;
Moher et al, 2010). This is termed intention-to-treat (ITT) analysis
and is the traditional statistical method when analysing data and
presenting comparative results (Hollis and Campbell, 1999). It
helps control selection bias and therefore confounding (Peto et al,
1976), and provides population estimates of the benefits and harms
of an intervention in practice (Sommer and Zeger, 1991). But using
an ITT analysis dilutes significant measures of effect. If we analyse
groups exactly as randomised when participants do not adhere to
the trial protocol, estimates attenuate towards the null and
statistical power is reduced (Newcombe, 1988; Sommer and
Zeger, 1991).
Although ITT estimates derived from RCTs are helpful when
planning policy, they are not suitable for individual decision
making about the potential effects of an intervention as received
(Baker et al, 2002). With screening mammography, estimates for
women invited to screening are attenuated compared with that for
women who actually attend screening. Control group estimates
contribute to attenuation when women seek out and attend
screening outside of the trial. This is because women who are
screened outside of the trial can be assumed to receive some benefit
and harm. This reduces the total number of breast cancer deaths in
the control group and inflates breast cancer incidence that would
underestimate mortality benefit and overdiagnosis. Furthermore,
individual participants are likely to have a preference for a
particular group to which they are randomised that can influence
adherence to the protocol.
This is often observed in RCTs of cancer screening (Hewitson
et al, 2007; Ilic et al, 2013). Nonadherence in the intervention
group – when participants do not attend screening – and in the
control group – when participants attend screening outside of the
trial – can be problematic. For example, in the most recent
screening mammography RCT, the UK Age Trial, adherence in the
intervention group was 68% (Moss et al, 2006). Although such
adherence rates may reflect real-world participation in screening
programmes, they are not helpful when estimating benefits and
harms for women who regularly attend screening and receive the
‘package’ as recommended by screening organisations. Thus,
alternative methods are required to provide unbiased estimates
of the effect of screening mammography on individuals.
Several meta-analyses of screening mammography of women in
the target age range of 50–75 years have been conducted using the
ITT principal, yet estimates of the effects remain contested (Wald
et al, 1993; Kerlikowske et al, 1995; Demissie et al, 1998; Blamey
et al, 2000; Humphrey et al, 2002; IARC, 2002; Nystro¨m et al, 2002;
Canadian Task Force on Preventive Health Care, 2011; Duffy et al,
2012; Gøtzsche and Jørgensen, 2013). Because of this ongoing
debate, in 2012 a group of independent experts from the United
Kingdom reviewed the benefits and harms of screening mammo-
graphy (Marmot et al, 2013). Their meta-analysis of the mortality
benefit of screening from nine trials was primarily based on 13
years of follow-up data reported in the Cochrane Review (Gøtzsche
and Nielsen, 2009). They reported a pooled relative risk reduction
(RRR) in breast cancer mortality of 20% among women invited to
screening. When determining harm due to overdiagnosis of breast
cancer, only the Malmo¨ I and Canada I and II trials were used
(Miller et al, 2000, 2002; Zackrisson et al, 2006). After 6–15 years
of follow-up, meta-analysis of these trials found an overdiagnosis
proportion of 19% during the screening period. These ITT
estimates of benefit and harm are useful for assessing the effect
of screening mammography on society. However, they do not
account for nonadherent participants and thus provide an
attenuated estimate of the effect of receiving screening and do
not reflect the effect on an individual.
Methods to obtain summary estimates from meta-analysis that
adjust for nonadherence yet respect the randomisation have been
developed for binary outcomes (Glasziou, 1992; Baker and
Lindeman, 1994; Cuzick et al, 1997), and pooled deattenuated
mortality estimates have previously been calculated for screening
mammography (Glasziou, 1992; Glasziou and Houssami, 2011). To
our knowledge, pooled deattenuated estimates of overdiagnosis
with meta-analysis have not been reported.
We attempt to answer the question from an individual woman’s
perspective, how large is the benefit of screening mammography
in terms of reduced risk of dying from breast cancer and how
substantial is the risk of harm in terms of overdiagnosis if she
decides to participate in a regular programme of screening
mammography? We aim to do this by deattenuating, that is,
adjusting for attenuation of the screening effect caused by women
who do not adhere to the trial protocol. We present pooled
estimates of the prevented fraction of mortality benefit and
percentage risk of overdiagnosis for RCTs of screening mammo-
graphy adjusted for nonadherence.
MATERIALS AND METHODS
Outline of approach. Our study built on the UK Panel 2012
systematic review of the benefit and harm of screening
mammography (Marmot et al, 2013). The Independent UK
Panel on Breast Cancer Screening reviewed the published work,
assessed the risk of bias in included studies and pooled results to
provide estimates of effect for the benefit and harm. Our
intention was to put into practice the recommendations made by
The Independent UK Panel report on Breast Cancer Screening to
provide ‘clear communication of these harms and benefits to
women’ (Marmot et al, 2013). We do this by deattenuating the
estimates of effect to reflect the efficacy of screening mammo-
graphy for women who actually attend. We combined data from
relevant mammography trials and extended the approach
previously described by Glasziou (1992) to conduct a random-
effects meta-analysis for mortality benefit and overdiagnosis risk.
This method enabled us to obtain a combined, deattenuated
prevented fraction: the proportion of deaths attributable to
breast cancer prevented by screening mammography. For the
combined, deattenuated estimate of overdiagnosis risk we
estimated the variance (with 95% confidence intervals (CIs))
for study-specific deattenuated estimates of overdiagnosis. Using
the combined results we were able to determine the effectiveness
of screening mammography on reducing breast cancer mortality
and the risk of overdiagnosis from the perspective of an average-
risk woman between the ages of 39 and 75 years who chooses to
participate ‘regularly’ in screening. ‘Regularly’ refers to the
screening interval across the trials that ranged from 12 to 33
months. Adherence refers to a person’s health-related behaviour
in accordance with the group assignment in a trial. We use the
term adherence rather than the tradition term compliance as this
reflects the active decision making of participants in a trial.
Compliance denotes passive obedience and has a paternalistic
connotation.
Data sources: mammography trials. Relevant studies were
identified from the Independent UK Breast Screening Review
(Marmot et al, 2013) that in turn sourced publications and data
from the Cochrane Review ‘Screening for breast cancer with
mammography’ (Gøtzsche and Nielsen, 2009). Only RCTs were
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used. When analysing the mortality benefit of screening mammo-
graphy, similar to the Independent UK Breast Screening Review
and Cochrane Review, we included 9 of the 11 available RCTs
in our analysis (NY HIP trial; Malmo¨ I; Swedish Two County:
Kopparberg and O¨stergo¨tland; Canada I and II; Stockholm;
Go¨teborg; and UK Age trial) (Shapiro et al, 1982; Taba´r et al,
1985; Andersson et al, 1988; Frisell et al, 1997; Miller et al,
2000, 2002; Bjurstam et al, 2003; Moss et al, 2006). The
Edinburgh trial was excluded because of imbalances between
groups in baseline socioeconomic level: 26% of the women in the
control and 53% in the screening group belonged to the highest
socioeconomic level (Alexander et al, 1999). Malmo¨ II was
excluded because of insufficient follow-up time (Andersson and
Janzon, 1997). Of the nine trials used to estimate mortality
benefit, three clearly did not offer screening to the control group
at the end of the active study period. Thus, when determining
harm due to overdiagnosis of breast cancer, only the Canada
I and II trials (Miller et al, 2000, 2002) and a subgroup of women
aged 55–69 years from the Malmo¨ I trial were used (Zackrisson
et al, 2006).
Data extraction. One author (GJ) independently extracted out-
come data from primary papers where possible. When the required
information was not obtainable, or there were discrepancies in
reporting of outcomes for the same trial, the author relied on the
Cochrane review (Gøtzsche and Nielsen, 2009). Extracted data
included: number of women randomised, adherence rates
(attendance in the intervention group and opportunistic screening
in the control group), number of breast cancers detected and breast
cancer mortality.
Adherence rates. Adherence rates were extracted from the
Cochrane review and primary studies (Shapiro et al, 1985; Taba´r
et al, 1985; Andersson et al, 1988; Frisell et al, 1997; Miller et al,
2000, 2002; Moss et al, 2006; Gøtzsche and Jørgensen, 2013). We
estimated adherence for one study: the HIP trial. Adherence in the
screened group was reported but adherence in the control group
was not. We assumed 100% adherence in the control group as
mammography was a relatively new technology and screening was
unlikely to be available outside of the trial during the active
screening period from December 1963 to June 1966 (National
Cancer Institute, 1978).
Deaths attributable to breast cancer (mortality rates). Breast
cancer mortality was taken from the Cochrane Review and primary
papers that reported the same length of follow-up of 13 years
(Shapiro et al, 1982; Andersson et al, 1988; Tabar et al, 1995; Frisell
et al, 1997; Miller et al, 2000, 2002; Bjurstam et al, 2003; Moss et al,
2006; Gøtzsche and Jørgensen, 2013).
Breast cancer cases (incidence rates). Information on breast
cancer diagnosis was obtained from the two Canadian trials (Miller
et al, 2000, 2002) and the Malmo¨ I trial for women aged 55–69
years (Zackrisson et al, 2006). Since the release of the Independent
UK Breast Screening Review, the 25-year follow-up data have been
published for the Canada trials (Miller et al, 2014). The two parts
of this trial, however, were not reported separately and thus the
data are not suitable for our analysis.
Trial numbers. Data on the number of women in each trial were
obtained from the Cochrane Review and primary studies (Shapiro
et al, 1982; Taba´r et al, 1985; Tabar et al, 1995; Frisell et al, 1997;
Miller et al, 2000, 2002; Bjurstam et al, 2003; Moss et al, 2006;
Gøtzsche and Jørgensen, 2013). Reported numbers vary consider-
ably for some trials. To ensure consistency and accuracy when the
exact sample size was in doubt we used the numbers reported in
the Cochrane Review.
Deattenuated estimates of effect
Mortality benefit. Glasziou (1992) proposed a method to adjust
the ITT estimate of the prevented fraction (PF) from RCTs
for nonadherence. The rationale is based on the linear model
of Newcombe (1988) for calculating a deattenuated estimate
in a single study that involves adjusting the observed
difference between the mean outcome for the intervention Y1ð Þ
and control Y2ð Þ group by a deattenuation factor (D) based on
the adherence proportions in the two groups (P1 and P2
respectively). The equation for the deattenuation factor is
given by:
D ¼ P1þP21
Hence, for a specific study, the deattenuated estimate of the
prevented fraction (DPFi) of an intervention effect is:
DPFi ¼
Y1iY2i
Di
For ease of interpretation, readers can think of the deattenuated
prevented fraction as a RRR, that is, the proportion of deaths
prevented by the intervention.
Glasziou (1992) also described a fixed-effect procedure to
combine the study-specific deattenuated estimates and compute a
summary estimate (DPF*) of the deattenuated Intervention effect.
Details of this along with formulas for the 95% CIs and variance
can be found in the Supplementary Material.
Overdiagnosis. For overdiagnosis, the Independent UK Panel
report percentage of risk for screened women. The panel’s
preferred method for measuring percentage overdiagnosis from
the perspective of an individual woman is method C, excess
cancers (5–10 years after screening ends) as a proportion
of all cancers diagnosed during the screening period in women
invited for screening (Marmot et al, 2013). The calculation for
this is:
ðCumulative incidence in the screened group
cumulative incidence in the control groupÞ
Total number of all breast cancers detected in
the screened group during the active screening period
As this is an outcome that can only occur in the screened group,
we use an attributable fraction. An explanation of the rationale
for this method of calculating overdiagnosis with examples can be
found in Welch and Black (2010). When conducting a meta-
analysis of percentage risk of overdiagnosis it is important that
the denominator includes screen-detected, interval and clinically
detected breast cancers in the screened group. This is because the
proportion of interval cancers relative to screen-detected cancers
increases as the screening interval increases. Excluding interval
breast cancers provides an estimate of overdiagnosis that is
dependent on screening frequency and applies only to one
particular trial. As we use trials with different screening intervals
(Canada I and II, 12 months; Malmo¨ I, 18–24 months) we must
account for this by including in the denominator all cancers
detected in the screened group.
The formula for the variance of the deattenuated estimate of
percentage risk of overdiagnosis (ODP) in the screened group was
computed assuming (1) an underlying binomial distribution for
percentage overdiagnosis and (2) D to be a constant. Using
standard variance formulae, the approximate variance of ODP for
study I is given by:
var
ODPi
D
 
¼ 1
D2
var ODPið Þ
where the study-specific percentage risk of overdiagnosis (ODi) is
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expressed as a proportion, D is a constant and the variance
formula is:
varðODPiÞ ¼ ODPið100ODPiÞni
For both the deattenuated estimates of prevented fraction and
overdiagnosis a random-effects summary estimate was calculated
using the method of (DerSimonian and Laird, 1986). We used the
I2 measure of heterogeneity to assess the extent to which the results
of individual studies were consistent (Higgins and Thompson,
2002). A spreadsheet was developed and statistical analyses
performed using Microsoft Excel software for the analyses. In
order to obtain and compare bias-corrected parameter estimates,
we bootstrapped the DerSimonian and Laird random-effects model
using the bdl option in metaan (Stata version 13, StataCorp LP,
College Station, TX, USA) to estimate the between-study variance
and heterogeneity parameters. Study-specific estimates and their
corresponding variance from the spreadsheet were input to metaan
to obtain summary estimates, 95% CIs and I2 based on 1000
replications.
Finally, we performed sensitivity analyses to account for the
uncertainty in the deattenuation factor, D. When data on the
proportion of women screened across all screening rounds were
available, we averaged this for individual trials (NY HIP trial;
Malmo¨ I; Kopparberg, O¨stergo¨tland; Canada I and II; Go¨teborg;
and UK Age Trial).
RESULTS
Adherence. Table 1 presents rates of adherence to trial protocol.
Figures ranged from 100% to 65% for the screened group and
100% to 76% for the control group.
Breast cancer-specific mortality benefit. Table 2 compares death
from breast cancer in screened vs control women. Figure 1 shows
the results from random-effects meta-analyses for both the ITT
and deattenuated estimates of the prevented fraction of breast
cancer mortality due to screening mammography. Estimates of
benefit increase with deattenuation, with a decrease in precision.
The overall ITT prevented fraction, comparing invited vs control
women, is 0.22 (95% CI 0.15–0.28). After adjusting for non-
adherence, the prevented fraction is 0.30 (95% CI 0.18–0.42). There
was moderate heterogeneity in the ITT prevented fractions across
different trials (I2¼ 36%, 95% CI 0–70.7%) that decreased slightly
with deattenuation (I2¼ 34%, 95% CI 0–69.8%).
Overdiagnosis. Table 3 compares breast cancer detection during
the entire follow-up period in screened vs control women. Figure 2
shows the results from random-effects meta-analyses for the two
estimates of percentage risk of overdiagnosis due to screening
mammography. An increase in overdiagnosis is observed with
deattenuation. The overall ITT percentage risk of overdiagnosis is
19.0% (95% CI 15.2–22.7%). After adjusting for nonadherence, the
percentage risk of overdiagnosis is 29.7% (95% CI 17.8–41.5%).
There was substantial heterogeneity in the ITT percentage risks of
overdiagnosis from the three trials (I2¼ 64.8%, 95% CI 0–89.9%)
that increased with deattenuation (I2¼ 92.0%, 95% CI 79.8–
96.8%). The corresponding bootstrap results are very similar.
Sensitivity analysis. When using an average of attendance in the
screened group across all screening rounds, the pooled deattenu-
ated prevented fraction increased to 0.34 (95% CI 0.21–0.47) and
the pooled deattenuated percentage risk of overdiagnosis also
increased to 32.1% (95% CI 20.3–44.0%).
DISCUSSION
Summary of key findings. We present the first combined,
deattenuated estimate of overdiagnosis from randomised con-
trolled trials of breast cancer screening for use when developing
quantitative information for individual women who participate
regularly in screening. The deattenuated percentage risk of
overdiagnosis of 30% for women who regularly attend screening
mammography during the screening period is considerably higher
than 19% estimate for invited women. The pooled deattenuated
prevented fraction estimate for breast cancer mortality from trials
is 0.30 for those who attended screening, again, considerably
greater than 0.20 for those invited.
Strengths
Random-effects model. We used a random-effects model to pool
the deattenuated estimates. When combining ITT estimates in a
fixed-effect meta-analysis, more weight may be given to studies
with poor adherence if they have a large sample size (Glasziou,
1992). A meta-analysis of deattenuated estimates avoids this
problem and previous studies have used this approach to combine
screening mammography trial estimates of mortality reduction
(Glasziou, 1992; Glasziou and Houssami, 2011). We used a
random-effects model as it is better suited to the heterogeneity
between screening mammography trials, for example differences in
the breast screening method, screening interval and number of
screening rounds (DerSimonian and Laird, 1986). Whilst the
assigned weights are more balanced, it produces wider confidence
intervals around the pooled estimate, reflecting a decrease in
precision (Higgins and Thompson, 2002). Although our analysis
should better allow for heterogeneity between trials that is
reflected in the reduced I2 for the DPF, the I2 for our deattenuated
Table 1. Adherence to the study protocol in the randomised trials of screening mammography
New York HIP Malmo¨ I Kopparberg O¨stergo¨tland Canada I Canada II Stockholm Go¨teborg UK Age Trial
Adherence
Screened 65% 74% 89% 90% 100% 100% 81% 84% 68%
Control 100% 76% 87% 87% 74% 83% 92% 82% 92%
Table 2. Number of breast cancer deaths and participants in
randomised trials of screening mammography
Number of breast
cancer deaths
Number of
participants
Screened Control Screened Control
New York HIP 218 262 31 000 31000
Malmo¨ I 87 108 20 695 20783
Kopparberg 126 104 38 589 18582
O¨stergo¨tland 135 173 38 491 37403
Canada I 105 108 25 214 25216
Canada II 107 105 19 711 19694
Stockholm 66 45 40 318 19943
Go¨teborg 88 162 21 650 29961
UK Age trial 105 251 53 884 106956
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estimate of overdiagnosis still suggests considerable remaining
heterogeneity.
Percentage risk of overdiagnosis during screening. When calcu-
lating percentage risk of overdiagnosis, different methods address
different questions. For individual women who are considering
screening, the most appropriate estimate of overdiagnosis is one
that presents the risk for regularly screened women, during the
active screening period (Marmot et al, 2013). This is because
overdiagnosis can only occur in women who are screened, and
including in the denominator cancers diagnosed after screening
ends dilutes the estimate of effect. Furthermore, it is important to
include both screen-detected and interval cancers as excluding
interval breast cancers provides an estimate of overdiagnosis that is
dependent on the screening interval. Our choice of estimate is in
line with the Independent UK Panel preferred measure of
percentage risk of overdiagnosis from the perspective of an
individual woman, Method C (Marmot et al, 2013).
Our deattenuated analysis avoids introducing selection bias
by preserving the ITT analysis. To calculate percentage risk of
overdiagnosis we compare outcome event rates among all
participants and then adjust that estimate to a degree determined
by the proportion of adherent participants in both arms of each
trial. As demonstrated by Newcombe (1988), this deattenuates
the estimate to what it would have been had there only been fully
adherent participants. Thus, our results are more relevant to
women who participate in screening and assumes that people
who attend screening in the trials are similar to those who attend
screening programmes. Deattenuation will not change the
estimate if there is no intervention effect or 100% adherence in
the study groups.
Limitations
Uncertainty. The deattenuated study-specific estimates diverge
from the unadjusted results. In part, this reflects the heterogeneity
between trials and uncertainty in study-specific estimates.
Although it is important to note the statistical uncertainty, as
indicated by the wide CIs that increase with deattenuation, there
are multiple sources of uncertainty that cannot be quantified,
including the methodological limitations of component studies.
Although our method avoids selection bias, this is only to the
extent that outcomes data are complete for all study participants.
Table 3. Number of breast cancers diagnosed in the three randomised trials of screening mammography suitable for estimating
overdiagnosis
Number of breast cancers diagnosed
during the entire follow-up period
Screened Control
Excess breast cancers
diagnosed in the screened
group at the end of follow-up
Breast cancers diagnosed
during the screening period
in women invited to screening
Malmo¨ I (55–69) 780 698 82 438
Canada I (40–49) 663 581 82 361
Canada II (50–59) 693 626 67 420
Study Prevented fraction
0.26 (0.01 – 0.47)
0.17 (0.00 – 0.30)
0.38 (–0.15 – 0.78)
0.19 (–0.07 – 0.39)
0.55 (0.32 – 0.72)
0.42 (0.24 – 0.55)
0.31 (0.07 – 0.51)
0.24 (0.05 – 0.39)
0.04 (–0.37 – 0.35)
0.03 (–0.27 – 0.26)
–0.02 (–0.40 – 0.27)
–0.02 (–0.33 – 0.22)
0.38 (–0.08 – 0.69)
0.27 (–0.06 – 0.50)
0.38 (0.04 – 0.64)
0.25 (0.03 – 0.42)
0.28 (–0.07 – 0.57)
0.17 (–0.04 – 0.34)
0.30 (0.18 – 0.42)
0.21 (0.13 – 0.30)
15.7
13.6
9.4
10.3
15.5
13.5
13.6
12.7
7.7
9.1
7.2
7.2
8.6
8.6
11.6
11.6
12.1
11.9
Weight
(%)
New York (1963)
Malmö I (1976)
Kopparberg (1977)
Östergotland (1978)
Canada I (1980)
Canada II (1980)
Stockholm (1981)
Göteborg (1982)
Uk age trial (1991)
Overall
–0.5 –0.3 –0.1 0 0.1 0.3 0.5 0.7 0.9
Prevented fraction
(PF) (95% Cl)
Figure 1. Meta-analysis of estimates of prevented fraction of breast cancer mortality after 13 years of follow-up with (blue) and without (grey)
adjustment for adherence. A full colour version of this figure is available at the British Journal of Cancer journal online.
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Fortunately with screening mammography trials, outcomes data
are near complete as cancer incidence and mortality events were
ascertained by reference to population-based cancer and death
registries. We acknowledge, however, that although follow-up rates
for outcomes were high (490%), they were not 100%. Further-
more, our estimates reflect a screening duration that ranges from 3
to 12 years, and may underestimate the prevented fraction and
overdiagnosis attributable to a 25-year screening period,
the recommended ‘package’ by many organisations including
those in Australia, the United States, Canada and, by 2016, the
United Kingdom (Canadian Task Force on Preventive Health Care,
2011; Moser et al, 2011; Department of Health Australia, 2016;
Siu, 2016), considerably longer than the screening periods
evaluated in the randomised trials. Finally, there is uncertainty
about the extent to which these estimates may be applicable to
contemporary screening mammography because of advances in
mammography technology, breast cancer treatment and an overall
reduction in breast cancer mortality.
When calculating the variance of the percentage risk of
overdiagnosis as a proportion of all cancers detected in the
screened group (Marmot method C), we have used a binomial
distribution in line with the Independent UK Panel (Marmot et al,
2013) and Baker et al (2014). When using a different denominator,
alternative methods may be more appropriate. Dealing with such
statistical issues is beyond the scope of this paper but warrants
further exploration.
Adherence. We used the adherence rate for the first round of
screening only, when attendance is highest. In reality, adherence is
a continuous variable. To reflect the full attenuation of the
estimates we would need to obtain adherence rates for all screening
rounds as the estimates of mortality benefit and overdiagnosis from
the trials reflect the impact of attendance at 2–10 mammograms.
Published data however do not allow for the multi-stage, interval
nature of screening. Even if it did, it is not clear how to partition
the benefit and harm for each screen as the contribution of
individual screening rounds to the overall observed mortality
reduction and overdiagnosis is unknown. Thus, it is likely that we
have underestimated the deattenuated effects.
Our analysis does not allow for participation in screening
programmes by either the intervention or control group after the
active screening period of the trial. Systematic screening of the
control group occurred in seven of the nine trials, but information
on attendance is not available for most studies. Continued
screening by the intervention group or uptake by the control
group after the end of the active screening period may have been
widespread because of the gradual introduction of mass screening
mammography during the 1980s in countries where the trials were
undertaken. Both of these issues would dilute the mortality
reduction and overdiagnosis estimates.
Methods to adjust for nonadherence in RCTs. The method used
in this paper to adjust for non-adherence was originally applied to
screening mammography trials by Glasziou (1992). There are
many reasons why our deattenuated breast cancer mortality
estimate differs to that original analyses conducted over 20 years
ago, where the pooled deattenuated prevented fraction for breast
cancer mortality was reported as 0.37. Of the five trials included in
the analysis of Glasziou (1992) (HIP, Swedish Two County,
Malmo¨, Edinburgh and Stockholm trials), we have excluded the
Edinburgh trial but used additional data from the Goteborg,
Canada I and II and UK Age trials. The original analysis of
Glasziou (1992) used women-years at risk as the denominator;
these data are not reported for all trials. We used number of
women as the denominator for mortality rate in line with the
Cochrane Review and the Independent UK Breast Screening
Review. Finally, using a random-effects model means the weights
assigned to each study are more balanced compared with the fixed-
effect analysis used by Glasziou.
Our deattenuated results also differ to those presented by
The Independent UK Breast Screening Review (Marmot et al,
2013). They reported a RRR for breast cancer mortality, adjusted
for nonadherence in the intervention group, of 25%. The methods
however are inexact. The authors estimated trial adherence in the
intervention group at 80% and divided the RRR of 20% by that
average attendance when adherence differed for individual trials,
ranging from 65% to 100%. Furthermore, they did not account for
nonadherence in the control groups across the trials that would
further attenuate the estimate of RRR and thus increase the
deattenuated RRR.
Alternative methods for adjustment have been described by
Cuzick et al (1997), Baker and Lindeman (1994) and Baker et al
(2016). The method of Cuzick et al (1997) involves stratifying the
probability of breast cancer mortality into four groups according to
women who are screened and not screened in both the control and
Study Overdiagnosis
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Figure 2. Meta-analysis of estimates of percentage risk of overdiagnosis of breast cancer with (blue) and without (grey) adjustment for
adherence. Overdiagnosis is measured from the perspective of an individual woman: excess cancers over the entire follow-up period as a
proportion of all cancers diagnosed during screening period in women invited for screening (as recommended by Independent UK Panel on Breast
cancer Screening (Marmot et al, 2013), Method C). A full colour version of this figure is available at the British Journal of Cancer journal online.
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screening arms. The assumption is that the underlying rate in
attenders is equivalent to that in the control group adjusted for the
rate in the nonattenders. Such detailed data are not reported for
most mammography trials. Baker and Lindeman (1994) and Baker
et al (2016) formulated the latent class IV method for binary
outcomes. They use four principal strata: always receivers who
would receive screening regardless of randomisation group,
compliers who would receive screening only if randomised to
screening, never takers and defiers. In each stratum, the response
to treatment differs. Estimates are based only on compliers, but
require assumptions about the different strata. A similar frame-
work was used by McIntosh (1999) to deattenuate mortality benefit
for the HIP Trial.
Implications. We present estimates that can be applied and used
to develop information on the benefit and harms of screening
mammography for individual women. To do so, we extended
existing methods to derive, for the first time, a deattenuated,
pooled estimate of percentage risk of overdiagnosis due to
screening mammography from three trials. The results demon-
strate the usefulness of this approach to other forms of cancer
screening where overdiagnosis may be a potential downside,
including prostate and lung cancer screening. The information can
be applied to local data to develop evidence-based numerical
outcomes for decision aids to help individuals weigh up the
benefits and harms of screening and make an informed choice, as
was done in a recent decision aid trial by Hersch et al (2015).
Likewise, it will assist clinicians in shared decision making as well
as policymakers when developing information materials about
cancer screening for individuals.
Methodological flaws and inconsistent reporting of results
within individual mammography trials highlight the need for
better standards of data collection and reporting by investigators.
Most lacking is information on the harms. More detailed
information on adherence to the trial protocol per screening
round could help to provide a more accurate reflection of
attendance and its impact on screening outcomes. This is especially
important for trials of emerging technology, including digital
mammography and tomosynthesis.
Finally, the uncertainty in the estimates and divergence of
individual study results after deattenuation, particularly with
overdiagnosis, further highlight the fact that there are few sources
of reliable data. Given that each year over 1.4 million women in
Australia and 2 million women in the United Kingdom attend
breast cancer screening, and they may rely on estimates such as
ours to help them weigh up the benefits and harms of screening to
make an informed choice, obtaining more precise numbers that
reflect changes since the original trials were conducted should be a
research priority.
CONCLUSION
Adjustment for nonadherence with the trial protocol increased
the size of both the mortality benefit and risk of over-
diagnosis by up to 50%. Deattenuated estimates better represent
the effects of screening mammography at an individual level, and
are useful for developing numerical outcomes for use by clinicians
and programmes to communicate risk and help women make
informed decisions – a guiding principle of modern health care.
This approach to the calculation of estimates of mortality benefit
and overdiagnosis of screening mammography that have been
adjusted for nonadherence is applicable to other cancer screening
trials.
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